PTIX (Protagenic Therapeutics) PB Ratio: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
22 GF Score
Price $0.18
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-01), Protagenic Therapeutics's share price is $0.18. Protagenic Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was $-1.24. Hence, Protagenic Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Protagenic Therapeutics's PB Ratio or its related term are showing as below:

PTIX's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.705
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Protagenic Therapeutics's average Book Value Per Share Growth Rate was -163.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -60.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Protagenic Therapeutics was -60.70% per year. The lowest was -60.70% per year. And the median was -60.70% per year.

Back to Basics: PB Ratio


Protagenic Therapeutics  (OTCPK:PTIX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Protagenic Therapeutics PB Ratio Related Terms


Protagenic Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics PB Ratio Chart

Protagenic Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.40 1.00 1.20 3.50

Protagenic Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.50 0.00 0.00 0.00 0.00

PTIX vs CERO, CYTOF, CARM: PB Ratio Comparison

For the Biotechnology subindustry, Protagenic Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's PB Ratio falls into.


PTIX
22GF Score
Protagenic Therapeutics Inc PTIX
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Protagenic Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.18/-1.237
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score

Get the complete analysis for PTIX

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price